Manejo da dor pós-operatória da cesariana
Manejo da dor pós-operatória da cesariana: um estudo prospectivo e observacional de coorte
Caesarean section is one of the most frequent surgeries causing severe postoperative pain. Poor management of acute pain can contribute to postoperative complications, late recovery and the development of chronic pain. Moreover, it had been demonstrated that the intensity of postpartum pain is associated with depression. It is imperative to find out appropriate methods of postpartum pain alleviation. Currently, a lot of analgesic drugs and methods have been developed and used in clinical practice, such as patient-controlled analgesia, extended-release analgesics and multimodal analgesia. This prospective cohort study is aimed to investigate the outcome of each postoperative analgesic method used in caesarean section.
Visão geral do estudo
Status
Status
Condições
Condições
Intervenção / Tratamento
Intervenção / Tratamento
Descrição detalhada
This is a prospective, observational, cohort study. Patients undergoing elective caesarean section will be invited to the study. The written informed consent will be obtained prior to participation. After getting the written informed consent, data will be collected from medical records, questionnaires, patient diaries, visit records and telephone visit records. Through telephone visits, postpartum depression scale and postpartum chronic pain will be evaluated six weeks and three months after delivery. Demographic data, consumption of analgesics, analgesic methods, intensity of postoperative pain, complications, recovery time, score of depression scale will all be summarized. Numerical variables will be present with mean and standard deviation and categorical variables will be present with number and percentage.
Tipo de estudo
Tipo de estudo
Inscrição (Real)
Inscrição
Contactos e Locais
Locais de estudo
-
-
-
New Taipei City, Taiwan, 251
- MacKay Memorial Hospital Tamsui Branch
-
Taipei, Taiwan, 104
- MacKay Memorial Hospital
-
-
Critérios de participação
Critérios de elegibilidade
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Método de amostragem
População do estudo
Pregnant woman scheduled to have caesarean section within 30 days.
Descrição
Inclusion Criteria:
- Aged 20 to 40.
- Planing to undergo caesarean section with spinal anesthesia.
- Scheduled to undergo cesarean section between 37 and 40 weeks of gestation.
- American Society of Anesthesiology Physical Class 1-2.
- Planing to alleviate postoperative pain with intravenous patient-controlled analgesia or administration of NALDEBAIN.
Exclusion Criteria:
- Not willing to provide informed consent.
- Unable to receive opioids or NSAIDs due to contraindication.
- Long-term use of opioids or drug abuse.
- Suffering from chronic pain disease.
- Having medical history of mental illnesses.
- Diagnosed with Pre-eclampsia or eclampsia.
- Diagnosed with gestational diabetes.
- Unsuitable for participation judged by investigator.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Modelos de observação: COHORT
- Perspectivas de Tempo: PROSPECTIVE
Número de grupos/coortes
Coortes e Intervenções
Grupo / CoorteGrupo / Coorte |
Intervenção / TratamentoIntervenção / Tratamento |
|---|---|
|
IV-PCA + NALDEBAIN group
Patients treated with the combination of IV-PCA and intramuscular injection of dinalbuphine sebacate will be allocated to IV-PCA + NALDEBAIN group. |
At the two trial sites, IV-PCA is commonly used with morphine. The device is installed after delivery and removed within 3 days.
Outros nomes:
Dinalbuphine sebacate is a prodrug of nalbuphine. With oil-based formulation, the active ingredient releases slowly and the effect lasts longer than nalbuphine. After delivery, a single 150 mg dose of dinalbuphine sebacate is administered intramuscularly.
Outros nomes:
|
|
IV-PCA group
Patients receiving intravenous patient-controlled analgesia (IV-PCA) will be allocated to IV-PCA group. |
At the two trial sites, IV-PCA is commonly used with morphine. The device is installed after delivery and removed within 3 days.
Outros nomes:
|
O que o estudo está medindo?
Medidas de resultados primários
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Postpartum pain intensity
Prazo: Within 5 days after delivery
|
Pain intensity is assessed by numerical rating scale (NRS) at least twice daily during hospital stay after delivery. NRS is a 11-point scale which labeled from zero (no pain) to ten (worst pain). The area under the curve of NRS are calculated. |
Within 5 days after delivery
|
Medidas de resultados secundários
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Consumption of analgesics
Prazo: Within 5 days after delivery
|
The mean total consumption of analgesics during the hospital stay after delivery. |
Within 5 days after delivery
|
|
Incidence of complications
Prazo: Up to 5 days after delivery
|
the incidence of postoperative complication occurring during hospital stay after delivery, especially the ones related to analgesics. |
Up to 5 days after delivery
|
|
Ambulation
Prazo: Up to 5 days after delivery
|
The mean length of time between delivery and the first ambulation. |
Up to 5 days after delivery
|
|
Breastfeeding
Prazo: Up to 5 days after delivery
|
The percentage of participants able to breastfeed during hospital stay and the mean length of time between delivery and the first breastfeeding. |
Up to 5 days after delivery
|
|
Gastrointestinal function recovery
Prazo: Up to 5 days after delivery
|
The mean length of time between delivery and first soft diet. |
Up to 5 days after delivery
|
|
Postnatal Depression assessment
Prazo: At baseline, 6 weeks and 3 months after delivery
|
Edinburgh Postnatal Depression questionnaire is used to assess patients' postpartum depression. Participants are asked to fill in the questionnaire at baseline (within 30 days prior to delivery), 6 weeks and 3 months after delivery. |
At baseline, 6 weeks and 3 months after delivery
|
|
Satisfaction assessed by a four-point scale
Prazo: 6 weeks after delivery
|
Participants are asked to assess the satisfaction toward rate of recovery progress and pain management through 6 questions six weeks after delivery. Each question contain 4 choices: very satisfied, satisfied, dissatisfied and very dissatisfied. |
6 weeks after delivery
|
|
Chronic pain intensity
Prazo: 6 weeks and 3 months after delivery
|
Chronic pain intensity is assessed by NRS 6 weeks and 3 months after delivery. NRS is a 11-point scale which labeled from zero (no pain) to ten (worst pain). |
6 weeks and 3 months after delivery
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Investigadores
Investigadores
- Investigador principal: Chi-Hsu Wang, M.D., MacKay Memorial Hospital Tamsui Branch
Publicações e links úteis
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Início do estudo
Conclusão Primária (Real)
Conclusão Primária
Conclusão do estudo (Real)
Conclusão do estudo
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Primeira postagem
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última Atualização Postada
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
- Dor
- Manifestações Neurológicas
- Doenças do Sistema Nervoso
- Complicações pós-operatórias
- Processos Patológicos
- Manifestações Neurocomportamentais
- Distúrbios Perceptivos
- Condições Patológicas, Sinais e Sintomas
- Sinais e sintomas
- Dor, Pós-operatório
- Agnosia
- Anestesia e analgesia
- Analgesia
- Analgesia, controlada pelo paciente
Outros números de identificação do estudo
Outros números de identificação do estudo
- 21MMHIS203e
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .